Rheumatoid Arthritis

 

Rheumatoid Arthritis With PTSD, Anxiety and Depression

October 16, 2020

Stress and anxiety can wreak havoc on one's health and hinder recovery, particularly for patients with chronic conditions, such as rheumatoid arthritis. In an article published online Sept. 13 in ACR Open Rheumatology, Joshua F. Baker, M.D., and colleagues report the results of study that finds veterans with rheumatoid arthritis and comorbid PTSD, depression, or anxiety, have poor persistence of methotrexate and TNFi therapies leading to worse outcomes. He addresses the study findings in this interview.

An Osteoarthritis Diagnosis of the Future May Be Driven by AI

October 14, 2020

Researchers have created a machine-learning algorithm that can detect subtle signs of osteoarthritis—too abstract to register in the eye of a trained radiologist—on an MRI scan taken years before symptoms even begin.

Rheumatoid Arthritis As Two Diseases

October 12, 2020

The underlying pathogenesis of rheumatoid arthritis with and without autoantibodies may be different. Researchers say that "it is time to formally subdivide RA into type 1 (with autoantibodies) and type 2 (without autoantibodies)."

One-on-one With Dr. Dimitrios Pappas: Etanercept as Monotherapy in RA

October 09, 2020

In today’s one-on-one interview, we talk with Dimitrios A. Pappas, M.D., MPH, scientific director of the Corrona RA Registry and an adjunct professor with Columbia University. He and his team recently published results from the registry in ACR Open Rheumatology which show that rheumatoid arthritis patients may be able to maintain remission or low disease activity with etanercept (Enbrel, Amgen) monotherapy long-term treatment.

The Art of Discontinuing Glucocorticoids in Rheumatoid Arthritis

September 04, 2020

Continuous low-dose glucocorticoid regimens are better than tapering for controlling disease activity in rheumatoid arthritis over a six-month period, show the results of the first double blind clinical trial to evaluate an oral glucocorticoid dose-tapering regimen with stable biological background therapy in rheumatoid arthritis.

DMARD Treatment for Early RA Improves Heart Disease

September 03, 2020

Vascular stiffness―which is often the precursor to a major cardiovascular event―appears to be present in early rheumatoid arthritis, shows a new study published in the Annals of the Rheumatic Diseases.

Methotrexate Not Associated with Lung Disease in RA

August 11, 2020

The prior use of methotrexate for rheumatoid arthritis patients doesn't seem to be associated with an increased risk of developing fibrotic interstitial lung disease, a common and potentially deadly complication of RA.

Diabetes More Common in PsA Than RA

August 06, 2020

Researchers writing in Arthritis Care and Research this week report that rheumatoid arthritis patients actually have a lower rate of type 2 diabetes than people without RA or patients with hypertension, osteoarthritis and psoriatic arthritis.

Podcast: Overdrive From Rheumatology Network with Dr. Jeffrey Sparks

August 02, 2020

In today's issue of Overdrive, a podcast from Rheumatology Network, we talk with Dr. Jeffrey Sparks, a rheumatologist with Brigham and Women’s Hospital in Boston who recently addressed the importance of an interdisciplinary and individualized approach in treating rheumatic disease patients who have Interstitial lung disease, a condition that can lead to worsen morbidity and mortality. Learn more in this interview.

Interdisciplinary Medicine Is Best in Rheumatology

July 31, 2020

In this week's news roundup from Rheumatology Network, we talk with Dr. Jeffrey Sparks, a rheumatologist with Brigham and Women’s Hospital in Boston who recently addressed the importance of an interdisciplinary and individualized approach in treating rheumatic disease patients who have interstitial lung disease, a condition that can lead to worsen morbidity and mortality. Learn more in this interview.

New RA Biosimilar Approved for U.S. Market

July 14, 2020

The U.S. FDA has approved the sixth biosimilar to Humira, adalimumab-FKJP (Hulio), which will be available in the United States in 2023 for rheumatoid arthritis, psoriatic arthritis, psoriasis, juvenile arthritis and other conditions.

Rheumatology News Roundup

July 13, 2020

In this week’s news roundup from Rheumatology Network, we highlight our most popular stories of the week including a one-on-one discussion with Dr. Vibeke Strand, a rheumatologist, immunologist and biopharmaceutical consultant who has conducted clinical trials on JAK inhibitors for rheumatoid arthritis. In this interview, Dr. Strand discusses this and other treatments in development for rheumatoid arthritis.